JAK2 and polycythemia: However, dual targeting of JAK2 and ERK1/2 via genetically induced ERK1/2 deficiency enhanced reduction of erythrocytosis in Jak2V617F settings, while no cytopenia occurred (Supplementary Fig. 5C-D).